BMS
BMS’ Opdivo accepted to UK early access scheme
June 30, 2015Sales and Marketing BMS, Cancer, NSCLC, eams, keytruda, opdivo
Bristol-Myers Squibb has scored another first with its new-generation oncology therapy Opdivo, which has become the first lung cancer drug …
ASCO 2015 roundup: immuno-oncology hits its stride
June 8, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASCO, BMS, CLL, pdl1
One year can make all the difference. The 2014 American Society of Clinical Oncology (ASCO) meeting took place just weeks …
BMS immunotherapy combination impresses at ASCO
June 1, 2015Research and Development, Sales and Marketing ASCO, BMS, Yervoy, opdivo
Bristol-Myers Squibb has presented data showing that a combination of its immunotherapies Opdivo and Yervoy significantly increases survival in advanced …
BMS’ Opdivo improves lung cancer survival
May 29, 2015Research and Development, Sales and Marketing ASCO, BMS, Bristol-Myers Squibb, NSCLC, lung cancer, nivolumab, non-small cell lung cancer, opdivo
A Phase III trial of Bristol-Myers Squibb’s immunotherapy Opdivo has found it increases overall survival in people with a common …
EMA recommends eight drugs for approval
May 22, 2015Sales and Marketing Amgen, BMS, EMA, Janssen, Merck, keytruda
The EMA has recommended eight medicines for approval in a round of reviews, including four new cancer indications. Amgen’s Repatha …
Merck to test Keytruda combinations
May 8, 2015Sales and Marketing BMS, Daiichi Sankyo, Merck, Plexxikon, keytruda, pembrolizumab
Merck will be teaming up with Daiichi Sankyo’s subsidiary Plexxikon to investigate immunotherapy combinations in cancer. A collaborative clinical trial …
FDA waves through generic BMS antipsychotic
April 30, 2015Manufacturing and Production, Sales and Marketing Alembic, BMS, FDA, Hetero and Torrent Pharmaceuticals, Teva
The FDA has approved four generic versions of Bristol-Myers Squibb’s top selling Abilify, an atypical antipsychotic drug approved to treat …
BMS lifted by new products
April 28, 2015Sales and Marketing BMS, NICE, Q1, eams, immuno-oncology and hepatitis C
New drugs have helped Bristol-Myers Squibb see a slight increase in sales for the first quarter of 2015. Total revenues …
EMA approves BMS’ Opdivo for advanced skin cancer
April 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer
Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …
BMS enters gene therapy development deal
April 7, 2015Research and Development BMS, Bristol-Myers Squibb, R&D, cardiovascular disease, cvd, heart disease, heart failure, uniQure
Bristol-Myers Squibb (BMS) has signed a multi-million dollar agreement with Amsterdam-based gene therapy firm uniQure to boost research into new …
BMS backs rheumatoid arthritis prevention trial
March 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, Orencia, RA, abatacept, rheumatoid arthritis
Bristol-Myers Squibb is funding a £3 million trial of Orencia as a preventative treatment for rheumatoid arthritis. The study will …
Merck’s Keytruda trial stopped early after beating BMS’ Yervoy on survival
March 25, 2015Research and Development, Sales and Marketing BMS, Merck, Yervoy, ipilimumab, keytruda, pembrolizumab
A trial comparing two potential blockbuster cancer treatments has been stopped early, after Merck’s Keytruda beat BMS’ Yervoy in a …
BMS resubmits hepatitis C drug
March 13, 2015Sales and Marketing BMS, NDA, daclatasvir gilead, hepatitis C, sovaldi
Bristol-Myers Squibb has resubmitted its hepatitis C (HCV) treatment for FDA approval despite previously backing out, as it spots a …
Anti-blood clotting drug Eliquis gets NICE nod
March 6, 2015Sales and Marketing BMS, DVT, Eliquis, NICE, Pfizer, Pradaxa, apixaban, clotting
Bristol-Myers Squibb and Pfizer’s Eliquis for preventing blood clots has been shown the green light to treat venous thromboembolism (VTE), …
BMS’ Opdivo wins US lung cancer race
March 5, 2015Research and Development, Sales and Marketing BMS, Prostvac, biosciences, flexus, lung cancer, oncology, opdivo
The FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with metastatic squamous non-small cell lung cancer …
